Study Design, Population, and Key Outcomes of DECLARE-TIMI 58 Compared With Other Cardiovascular Outcomes Trials for Sodium-Glucose Cotransporter-2 Inhibitors

Article Type
Changed
Tue, 05/03/2022 - 15:15
Display Headline
Study Design, Population, and Key Outcomes of DECLARE-TIMI 58 Compared With Other Cardiovascular Outcomes Trials for Sodium-Glucose Cotransporter-2 Inhibitors

Click here to read the supplement

Topics Include:

  • The cardiovascular (CV) safety and efficacy of the sodium-glucose cotransporter-2 inhibitor (SGLT-2i) dapagliflozin was evaluated in the DECLARE-TIMI 58 study.
  • The study design and patient population of DECLARE-TIMI 58 differed from those of other CV outcomes trials of SGLT-2is (EMPA-REG OUTCOME and CANVAS)
  • Key outcome results between the 3 CV outcomes trials of SGLT-2is may have been affected by variations in the study designs and patient populations, given that DECLARE-TIMI 58 evaluated a larger population of patients with type 2 diabetes (T2D) without prior CV events than the EMPA-REG OUTCOME or CANVAS studies, potentially allowing for a broader generalizability of the study results to patients with T2D in real-world clinical practice.

 

Click here to read the supplement

 

About the Author:

Bulent S. Atac, MD
Albert Einstein College of
Medicine and Montefiore Medical Center,
Bronx, New York

Sponsor
Funding for this newsletter series was provided by AstraZeneca
Publications
Topics
Sections
Sponsor
Funding for this newsletter series was provided by AstraZeneca
Sponsor
Funding for this newsletter series was provided by AstraZeneca

Click here to read the supplement

Topics Include:

  • The cardiovascular (CV) safety and efficacy of the sodium-glucose cotransporter-2 inhibitor (SGLT-2i) dapagliflozin was evaluated in the DECLARE-TIMI 58 study.
  • The study design and patient population of DECLARE-TIMI 58 differed from those of other CV outcomes trials of SGLT-2is (EMPA-REG OUTCOME and CANVAS)
  • Key outcome results between the 3 CV outcomes trials of SGLT-2is may have been affected by variations in the study designs and patient populations, given that DECLARE-TIMI 58 evaluated a larger population of patients with type 2 diabetes (T2D) without prior CV events than the EMPA-REG OUTCOME or CANVAS studies, potentially allowing for a broader generalizability of the study results to patients with T2D in real-world clinical practice.

 

Click here to read the supplement

 

About the Author:

Bulent S. Atac, MD
Albert Einstein College of
Medicine and Montefiore Medical Center,
Bronx, New York

Click here to read the supplement

Topics Include:

  • The cardiovascular (CV) safety and efficacy of the sodium-glucose cotransporter-2 inhibitor (SGLT-2i) dapagliflozin was evaluated in the DECLARE-TIMI 58 study.
  • The study design and patient population of DECLARE-TIMI 58 differed from those of other CV outcomes trials of SGLT-2is (EMPA-REG OUTCOME and CANVAS)
  • Key outcome results between the 3 CV outcomes trials of SGLT-2is may have been affected by variations in the study designs and patient populations, given that DECLARE-TIMI 58 evaluated a larger population of patients with type 2 diabetes (T2D) without prior CV events than the EMPA-REG OUTCOME or CANVAS studies, potentially allowing for a broader generalizability of the study results to patients with T2D in real-world clinical practice.

 

Click here to read the supplement

 

About the Author:

Bulent S. Atac, MD
Albert Einstein College of
Medicine and Montefiore Medical Center,
Bronx, New York

Publications
Publications
Topics
Article Type
Display Headline
Study Design, Population, and Key Outcomes of DECLARE-TIMI 58 Compared With Other Cardiovascular Outcomes Trials for Sodium-Glucose Cotransporter-2 Inhibitors
Display Headline
Study Design, Population, and Key Outcomes of DECLARE-TIMI 58 Compared With Other Cardiovascular Outcomes Trials for Sodium-Glucose Cotransporter-2 Inhibitors
Sections
Disallow All Ads
Content Gating
No Gating (article Unlocked/Free)
Alternative CME
Disqus Comments
Off
Gate On Date
Mon, 11/19/2018 - 14:00
Un-Gate On Date
Mon, 11/19/2018 - 14:00
Use ProPublica
CFC Schedule Remove Status
Mon, 11/19/2018 - 14:00